Variations in insurance coverage for autologous bone marrow transplantation for breast cancer

Kenneth J. Krause; Charles M. Cutler; I. Steven Udvarhelyi; William Winkenwerder; John K. Erban; Katherine M. Templeton; John R. Wingard; Vikram Khanna; William P. Peters; Mark C. Rogers

doi:10.1056/NEJM199408043310514

Variations in insurance coverage for autologous bone marrow transplantation for breast cancer

Kenneth J. Krause, Charles M. Cutler, I. Steven Udvarhelyi, William Winkenwerder, John K. Erban, Katherine M. Templeton, John R. Wingard, Vikram Khanna, William P. Peters, Mark C. Rogers

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Abstract

To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)¹ assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.

Original language	English (US)
Pages (from-to)	329-331
Number of pages	3
Journal	New England Journal of Medicine
Volume	331
Issue number	5
DOIs	https://doi.org/10.1056/NEJM199408043310514
State	Published - Aug 4 1994
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199408043310514

Cite this

@article{f5617370b6d04771a6647ceebdb90143,

title = "Variations in insurance coverage for autologous bone marrow transplantation for breast cancer",

abstract = "To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)1 assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.",

author = "Krause, {Kenneth J.} and Cutler, {Charles M.} and Udvarhelyi, {I. Steven} and William Winkenwerder and Erban, {John K.} and Templeton, {Katherine M.} and Wingard, {John R.} and Vikram Khanna and Peters, {William P.} and Rogers, {Mark C.}",

year = "1994",

month = aug,

day = "4",

doi = "10.1056/NEJM199408043310514",

language = "English (US)",

volume = "331",

pages = "329--331",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "5",

}

TY - JOUR

T1 - Variations in insurance coverage for autologous bone marrow transplantation for breast cancer

AU - Krause, Kenneth J.

AU - Cutler, Charles M.

AU - Udvarhelyi, I. Steven

AU - Winkenwerder, William

AU - Erban, John K.

AU - Templeton, Katherine M.

AU - Wingard, John R.

AU - Khanna, Vikram

AU - Peters, William P.

AU - Rogers, Mark C.

PY - 1994/8/4

Y1 - 1994/8/4

N2 - To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)1 assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.

AB - To the Editor: In concluding that the current process for making decisions about coverage of high-dose chemotherapy for breast cancer is “arbitrary and capricious,” Drs. Peters and Rogers (Feb. 17 issue)1 assume that … only insurers have a financial interest in making determinations about coverage. At the commonly quoted price of $150,000 per course of treatment, however, treatment of the 533 women in their analysis represents an annual income of $20 million to their institution alone. Institutions, providers, and suppliers all benefit substantially from insurance coverage for this treatment. Though the authors indicate otherwise, publication of their article.

UR - http://www.scopus.com/inward/record.url?scp=0027965632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027965632&partnerID=8YFLogxK

U2 - 10.1056/NEJM199408043310514

DO - 10.1056/NEJM199408043310514

M3 - Letter

C2 - 8022449

AN - SCOPUS:0027965632

SN - 0028-4793

VL - 331

SP - 329

EP - 331

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -

Variations in insurance coverage for autologous bone marrow transplantation for breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this